Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden

Next Previous
X
Search
Trial Profile

The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camostat mesilate (Primary)
  • Indications COVID-19 respiratory infection
  • Focus Therapeutic Use
  • Acronyms COV-AAT

    • Most Recent Events

    • 08 Aug 2024 Status changed from recruiting to discontinued.
    • 01 Sep 2022 Primary endpoint (Efficacy in terms of viral load or surrogate) has not been met, as per results published in the International Journal of Infectious Diseases.
    • 01 Sep 2022 Results (n=96; between November 2020 and June 2021) assessing the efficacy and safety of 300 mg camostat mesylate three times daily in a fasted state to treat early phase COVID-19 in an ambulatory setting, published in the International Journal of Infectious Diseases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top